AMT Medical security secures $25M 来推进其创新性心脏绕心系统,目标是到2026年实现市场化。 AMT Medical secures $25M to advance its innovative heart bypass system, aiming for market by 2026.

荷兰一家医疗技术公司AMT Medical公司获得2 500万美元的资金,用于推进其ELANAQ心脏绕行系统,这是一种最小侵入性技术,旨在对冠动脉绕行手术进行革命。 AMT Medical, a Dutch medtech firm, secured $25 million in funding to advance its ELANA® Heart Bypass System, a minimally invasive technology aimed at revolutionizing coronary artery bypass surgery. 该系统使用专用剪片和激光将没有缝合的血管连接起来,有可能减少并发症和费用。 The system uses a proprietary clip and laser to connect blood vessels without sutures, potentially reducing complications and costs. 这笔资金将支持CE标记和美国临床试验,目标是在2026年之前将技术投放市场。 The funding will support CE marking and U.S. clinical trials, with the goal of bringing the technology to market by 2026.